Alliancells Bioscience

Alliancells Bioscience is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of advanced cell therapies. The company focuses on utilizing induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC) technologies to address life-threatening conditions, particularly in the fields of hepatology and immunology. Their lead candidate, AC-101, is currently in Phase 2 clinical trials for the treatment of acute-on-chronic liver failure. Alliancells operates an integrated platform that encompasses research, process development, and large-scale GMP manufacturing. By leveraging its proprietary technology, the company aims to provide standardized, off-the-shelf regenerative medicine products to patients globally.